Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 5,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Lung Cancer Clear all

Conditions: COVID-19
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 23 Years to 35 Years · Female only
Enrollment: 1,197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Bladder Cancer, Kidney Cancer, Stomach Cancer, Colorectal Cancer, Pancreas Cancer, Liver Cancer, Skin Cancer
Interventions: Blood Sample Collection; Other
Lead sponsor: Delfi Diagnostics Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 2,992 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 56
States / cities: Homewood, Alabama • Peoria, Arizona • Fayetteville, Arkansas + 49 more

Conditions: Thyroid Cancer, Colon Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer
Interventions: ETBX-011, ALT-803; Biological
Lead sponsor: NantCell, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Lung Cancer (Locally Advanced or Metastatic)
Interventions: Pemefolacianine Cohort 1 in Part A, Pemefolacianin Cohort 2 in Part B; Drug
Lead sponsor: Sunil Singhal; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non Small Cell Lung Cancer
Interventions: Zanidatamab, Zongertinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Cancer
Interventions: Not listed
Lead sponsor: Southern Illinois University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 10,000 participants
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Springfield, Illinois

Conditions: Primary Lung Cancer, Benign Lung Disease, Thymoma, Myasthenia Gravis
Interventions: Robotic-Assisted Surgery; Device
Lead sponsor: Intuitive Surgical; Industry
Eligibility: 21 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York + 2 more

Conditions: Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, NSCLC
Interventions: Radiation Therapy, Paclitaxel, Carboplatin, Ascorbic Acid; Drug
Lead sponsor: Joseph J. Cullen, MD, FACS; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Appendix Adenocarcinoma, Human Papillomavirus-Related Anal Squamous Cell Carcinoma, Human Papillomavirus-Related Cervical Squamous Cell Carcinoma, Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis, Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma, Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Tumor, Recurrent Merkel Cell Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Peritoneal Malignant Mesothelioma, Recurrent Pleural Malignant Mesothelioma, Stage III Merkel Cell Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage III Pleural Malignant Mesothelioma AJCC v7, Stage IV Merkel Cell Carcinoma AJCC v7, Stage IV Nasopharyngeal Carcinoma AJCC v7, Stage IV Pleural Malignant Mesothelioma AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7, Stage IVB Nasopharyngeal Carcinoma AJCC v7, Stage IVC Nasopharyngeal Carcinoma AJCC v7, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
Interventions: Atezolizumab, Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Biological · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-Small-Cell Lung Cancer
Interventions: Ispinesib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 7
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 4 more

Conditions: Nicotine Dependence, Other Tobacco Product, Bladder Cancer, Lung Cancer, Cancer of Head and Neck
Interventions: HALO; Device
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Carcinoma, Non Small Cell Lung (NSCLC)
Interventions: Carboplatin, Paclitaxel, Daily hyperfractionated radiation therapy; Drug · Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Non Small Cell Lung Cancer, Cardiotoxicity, Locally Advanced Non-Small Cell Lung Cancer, Radiation Therapy
Interventions: PET/CT 18F-Flurpiridaz Rest/Stress Test, Coronary CT Angiography (CCTA), 18F-Flurpiridaz; Diagnostic Test · Device · Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Lung Cancer
Interventions: Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non Small Cell Lung Cancer (NSCLC)
Interventions: semi-allogeneic human fibroblasts (MRC-5) transfected with DNA; Biological
Lead sponsor: Theresa Whiteside, PhD; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Cancer-Associated Thrombosis (CAT)
Interventions: REGN7508, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Hialeah, Florida • North Miami Beach, Florida • Boston, Massachusetts + 2 more

Conditions: Lung Cancer
Interventions: CPAP; Device
Lead sponsor: Mark M. Fuster, MD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Lung Cancer
Interventions: RAD001; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Kidney Cancer, Lung Cancer, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: sargramostim, flow cytometry, immunoenzyme technique, biopsy, cryosurgery; Biological · Other · Procedure
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell), Pancreas Cancer, Duct Cell Adenocarcinoma
Interventions: ADC; Drug
Lead sponsor: MBrace Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 7
States / cities: San Francisco, California • Grand Rapids, Michigan • East Brunswick, New Jersey + 4 more

Conditions: NSCLC, Non Small Cell Lung Cancer
Interventions: OSI-906, Erlotinib, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 13
States / cities: La Jolla, California • Tampa, Florida • Weston, Florida + 8 more

Conditions: Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer, Stage IV Prostate Cancer, Stage IV Pancreatic Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Cancer, Stage IV Fallopian Tube Cancer, Stage IV Colon Cancer, Stage IV Colorectal Cancer, Stage IV Liver Cancer, Stage IV Renal Cell Cancer, Stage IV Rectal Cancer, Stage IV Lung Cancer, Stage IV Small Intestinal Cancer, Stage IV Gastric Cancer, Stage IV Bladder Cancer
Interventions: Canady Helios Cold Plasma Scalpel; Device
Lead sponsor: Jerome Canady, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: [18F]F-AraG Injection; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metastatic Cancer
Interventions: Genetically Informed Therapy; Genetic
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Search by objective public record fields.

COVID-19 Experiences in the SELF Cohort

DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)

QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

Pemefolacianine for IMI of Lung Cancer

A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC)

Rural Illinois Lung Cancer Screening Initiative

SP Thoracic IDE Study

A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer

Evaluation of Appeal and Impact of E-Cigarettes Among Chronic Smokers With Smoking-Related Cancers

Locally Advanced NSCLC Hyperfractionated RT

Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Gene Polymorphisms and Symptoms in Lung Cancer Patients

Immunization of Patients With Non Small Cell Lung Cancer (NSCLC)

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

Early Diagnosis and Treatment of Sleep Disordered Breathing in Lung Cancer

Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites

PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)

Genetically-informed Therapies for Patients With Metastatic Cancer